Trials / Terminated
TerminatedNCT05148442
A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor
A Phase Ia/Ib Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in Myeloid tumor patients.
Detailed description
Phase 1a/1b study will be conducted to evaluate the tolerability, safety, PK, PD, immunogenicity and preliminary antitumor activity of IBI322 in patients with myeloid tumor. Phase 1a is the dose escalation part of the study and Phase 1b is the dose expansion part. Combination therapy with HMA(Azacitidine or Decitabine) will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI322 | Recombinant anti-human CD47/PD-L1 bispecific antibody |
Timeline
- Start date
- 2021-12-28
- Primary completion
- 2023-06-19
- Completion
- 2023-08-29
- First posted
- 2021-12-08
- Last updated
- 2023-09-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05148442. Inclusion in this directory is not an endorsement.